로그인 회원가입
icon_bulk_order대량 주문 Acrobiosystems for English
0
장바구니가 비어 있습니다
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: > FGF-21

FGF-21

요약

Name:Fibroblast growth factor 21
Target Synonym:FGF21
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:8
Lastest Research Phase:Phase 3 Clinical

라이센싱

Project Name Modality Therapeutic Area Indications Stage Right Available
GIP/GLP-1/FGF21 Fusion Protein treating NASH, T2DM, Hyperlipoidemia NASH, T2DM, Hyperlipoidemia Preclinical

제품 리스트 구매

제품 상태별:
제품 유형별 :
종별:
제품번호 제품 설명 구조 순도 특징
FG1-H82Q3 Human Biotinylated Human FGF-21 Protein, His,Avitag™
FG1-H82Q3-structure
FG1-H82Q3-sds
FG1-H5243 Human Human FGF-21 Protein, His Tag
FG1-H5243-structure
FG1-H5243-sds

Synonym Name

FGF-21, FGF21

Background

Fibroblast growth factor 21 (FGF21), which stimulates glucose uptake in differentiated adipocytes via the induction of glucose transporter SLC2A1/GLUT1 expression. FGF21 has been shown to protect animals from diet-induced obesity when overexpressed in transgenic mice. It also lowers blood glucose and triglyceride levels when administered to diabetic rodents, suggesting it may exhibit the therapeutic characteristics necessary for effective treatment of diabetes. Treatment of animals with FGF21 results in increased energy expenditure, fat utilisation and lipid excretion. FGF21 is most abundantly expressed in the liver, and also expressed in the thymus at lower levels.

Clinical and Translational Updates

임상 약품 정보

Name Research Code Research Phase Company Indications Clinical Trials
Pegozafermin BIO89-100; TEV-47948 Phase 2 Clinical 89bio Inc, Teva Hypertriglyceridemia; Non-alcoholic Fatty Liver Disease Details
BOS-580 Phase 2 Clinical Novartis Pharma Ag Non-alcoholic Fatty Liver Disease Details
HEC-88473 HEC-88473 Phase 1 Clinical Dongguan City Hec Biological Medicine Res And Development Co Ltd Non-alcoholic Fatty Liver Disease; Diabetes Mellitus, Type 2; Obesity Details
Recombinant human FGF21 Fc fusion protein(Anyuan Pharmaceutical) AP-025 Phase 1 Clinical Anyuan Pharmaceutical Technology (Shanghai) Co Ltd Non-alcoholic Fatty Liver Disease Details
AP-026 AP-026 Phase 1 Clinical Anyuan Pharmaceutical Technology (Shanghai) Co Ltd Non-alcoholic Fatty Liver Disease Details

This web search service is supported by Google Inc.

totop